IP Library Granted Patent US 12702697
Granted Patent B2
US 12702697 · App. 17/787,026 · Granted Aug 11, 2026

Compositions and methods for treatment of headache disorders and neuropathic pain

Inventors: Yu-Qing Cao (St. Louis, MO); Zhiyu Zhang (St. Louis, MO); Rong Hu (St. Louis, MO); Jintao Zhang (St. Louis, MO); Megan E. Cloud (St. Louis, MO)
Assignee: Washington University
A61K38/2013A61K40/11A61K40/22A61K40/414A61P25/00A61K2239/31A61K2239/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12702697
App. No.
17/787,026
Granted
Aug 11, 2026
Kind
B2
Abstract

Among the various aspects of the present disclosure is the provision of compositions and methods of treating or preventing various headache disorders or neuropathic pain by increasing the number of Treg cells in a subject. In particular, low dose IL-2, rapamycin, statin or Treg cell administration are shown to be useful in treating or preventing headache or neuropathic pain.

Claims (9)

1 . A method of treating a headache in a subject in need thereof, the method comprising, systemically administering a composition comprising Interleukin-2 (IL-2) at a dose of about 0.05 MIU/m 2 /day to less than 3.5 MIU/m 2 /day that increases the amount of Treg cells in the subject daily for at least 6 days, wherein at least one symptom of the headache is reduced.

2 . The method of claim 1 , wherein the headache is a migraine, tension-type headache, cluster headache, medication-overuse headache, or trauma induced acute or chronic headache.

3 . The method of claim 1 , wherein IL-2 is administered at a dose of about 0.05 MIU/m 2 /day to about 2 MIU/m 2 /day.

4 . The method of claim 1 , wherein IL-2 is administered at a dose of about 2 MIU/m 2 /day.

5 . The method of claim 1 , wherein the IL-2 is administered repeatedly.

6 . The method of claim 1 , wherein the IL-2 is administered daily for more than 7 days.

7 . The method of claim 1 , wherein the IL-2 is administered once per day for 4 to 5 consecutive days.

8 . The method of claim 1 , wherein the IL-2 administration is followed by a maintenance dose after 1 to 4 weeks.

9 . The method of claim 1 , wherein IL-2 is administered by subcutaneous route.